ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07187713
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Ace Cells Lab Limited
- Registry
-
NCT07187713
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Recruiting
Technical summary
Registry record NCT07187713. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-20 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
- Acronym
- ACE Reno
- Condition
- Hypertensive Nephropathy
- Condition
- Auto Immune Disorders
- Condition
- Chronic Kidney Disease
- Condition
- Chronc Kidney Disease Stage 5
- Condition
- Chronic Kidney Disease (Stage 3-4)
- Condition
- Chronic Kidney Disease (Stages 4 and 5)
- Condition
- Microalbuminuria
- Condition
- Diabetic Nephropathies
- Intervention (Drug)
- ACE Reno
- Lead sponsor
- Ace Cells Lab Limited
Record details
- Record id
cardio:ct-nct07187713- Content hash
a94b850b67239c0194df4544e264a4a9bdaecc49eb542ce13d7eca5006efd356